Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | BAD | Q92934 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216565 | 0.82 | ITGB2 (0.39) | ALDH1A1HSD17B10 | |
| SCHEMBL9738660 | 0.82 | KDM4E (0.41) | ALDH1A1HSD17B10TDP1CYP3A4GSK3B | |
| SCHEMBL3404505 | 0.80 | ABCG2 (0.37) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 | |
| SCHEMBL6904035 | 0.78 | ABCG2 (0.36) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 | |
| SCHEMBL83574 | 0.78 | NQO2 (0.40) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 | |
| SCHEMBL4060952 | 0.74 | TAAR1 (0.33) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 | |
| SCHEMBL63619 | 0.74 | AOC3 (0.35) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 | |
| SCHEMBL8612149 | 0.74 | CHRNB2 (0.35) | ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL2884931 | 0.70 | ABCG2 (0.52) | ABCG2CYP3A4PKMTSHR | |
| SCHEMBL910176 | 0.62 | ITGB2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020195437-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | 協和ファーマケミカル株式会社 | 2020-10-01 | — | — | WO | disclosed |
| EP-3015472-B1 | COMPOUND, MANUFACTURING METHOD THEREFOR, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE ALPHA-AMINOPHOSPHONATE DERIVATIVE | MICROBIAL CHEM RES FOUND (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-2679580-B1 | THIOAMIDE COMPOUND, METHOD FOR PRODUCING THIOAMIDE COMPOUND, METHOD FOR PRODUCING [(4R,6R)-6-AMINOETHYL-1,3-DIOXAN-4-YL]ACETATE DERIVATIVE, AND METHOD FOR PRODUCING ATORVASTATIN | MICROBIAL CHEM RES FOUND (JP) | 2017-08-09 | — | — | EP | disclosed |
| EP-3199524-A1 | OPTICALLY ACTIVE -TRIFLUORMETHYL- -AMINO ACID DERIVATIVE PRODUCTION METHOD | Microbial Chemistry Research Foundation (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9493492-B2 | Compound, manufacturing method therefor, and method for manufacturing optically active α-aminophosphonate derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2016-11-15 | — | — | US | disclosed |
| US-20160145278-A1 | Compound, Manufacturing Method Therefor, and Method for Manufacturing Optically Active alpha-Aminophosphonate Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2016-05-26 | — | — | US | disclosed |
| EP-3015472-A1 | COMPOUND, MANUFACTURING METHOD THEREFOR, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE -AMINOPHOSPHONATE DERIVATIVE | Microbial Chemistry Research Foundation (JP) | 2016-05-04 | — | — | EP | disclosed |
| EP-2611819-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Takasago International Corporation (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029970-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145278-A1 | Compound, Manufacturing Method Therefor, and Method for Manufacturing Optically Active alpha-Aminophosphonate Derivative | AGPS, GGPS1, AASDHPPT | ABCG2 1552/4885TXNRD1 4851/4885TXNRD3 4796/4885 |
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | ABCG2 1424/4885TXNRD1 3450/4885TXNRD3 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.